{"id":474506,"date":"2021-04-10T08:33:35","date_gmt":"2021-04-10T12:33:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474506"},"modified":"2021-04-10T08:33:35","modified_gmt":"2021-04-10T12:33:35","slug":"oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/","title":{"rendered":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Xerna\u2122 TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Data supports the application of Xerna\u2122 TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna\u2019s clinical-stage programs <\/em>\n      <\/p>\n<p align=\"justify\">WALTHAM, Mass., April  10, 2021  (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna\u2122 TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna\u2122 platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over 600 CRC patients. The Xerna\u2122\u00a0TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on their dominant biologies of the tumor microenvironment (TME), and has been developed as a clinical assay.<\/p>\n<p align=\"justify\">\u201cOur goal is to expand the applicability of precision medicine in cancer through a novel approach that matches patients to the appropriate therapies by using RNA expression to identify patients with common biological drivers,\u201d said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. \u201cIn our AACR presentation, we presented results that verify the capabilities of our TME Panel and enable its expanded use for patients with colorectal cancer. These exciting findings pave the way for future prospectively-driven trials with the Xerna\u2122 TME Panel and our clinical-stage programs, navicixizumab and bavituximab.\u201d<\/p>\n<p align=\"justify\">The results from the study presented at this year\u2019s AACR Annual Meeting revealed:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">An expansion of the TME Panel\u2019s capabilities to include CRC, as the RNA-based gene signature identified unique subtypes of patients with angiogenic and immune biologies that dominated the stroma. These biologies were prognostic for recurrence-free and overall survival, supporting the potential use of the TME Panel as a novel, pan-tumor biomarker.\n<\/li>\n<li style=\"text-align:justify\">A comparison of the TME Panel\u2019s subtypes to the Consensus Molecular Subtypes (CMS) model. The CMS model represents gene expression data from both colorectal cancer cells and their microenvironment. In contrast, the Xerna\u2122 TME Panel integrates the interplay of angiogenic and immunogenic properties of the tumor microenvironment, and because of this focus, could be more predictive for treatments that target angiogenic and immunogenic properties of the TME.<\/li>\n<\/ul>\n<p align=\"justify\">The following two datasets were used to explore the application of the TME Panel in colorectal cancer: 1) A public dataset from the Cartes d\u2019Identite des Tumeurs (CIT) containing 566 primary tumor samples collected from patients with stage 1-4 CRC between 1988 and 2007 in France, and 2) A proprietary collection of 92 samples from the Wood Hudson Cancer Research Laboratory (WH) of patients with metastatic CRC who were treated with various regimens including targeted therapies following surgery.<\/p>\n<p align=\"justify\">OncXerna\u2019s electronic poster, #348 entitled: \u201cRNA-based Diagnostic Panel Matches TME Phenotype to Therapeutic Mechanism of Action in Colorectal Cancer,\u201d is included in the \u201cBiomarkers Predictive of Therapeutic Benefit\u201d poster session at the AACR annual meeting. A link to the poster can be found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_T2_5Au-kb3Lv2POjUuEzbO_WSpo8rlQ2DBqgvj6K_j8mj7MJl3IhEzomVXsE2-YM2vzyinlPLkog0vgFe3d9g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About OncXerna Therapeutics, its Xerna\u2122 RNA-based Biomarker Platform, and Xerna\u2122 TME Panel <\/strong>\n      <\/p>\n<p align=\"justify\">OncXerna plans to deliver next-generation precision medicine to a larger group of cancer patients by leveraging the company\u2019s Xerna\u2122 platform to prospectively identify patients based on the dominant biology of their cancer. This allows OncXerna to pair those patients with OncXerna\u2019s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. The Xerna\u2122\u00a0TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the TME, and has been developed as a clinical assay. The Xerna\u2122 TME Panel is an investigational assay that has not been licensed or approved, and has not been demonstrated to be safe or effective for any use.<\/p>\n<p align=\"justify\">For more information on OncXerna, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NCMwWT-FSRxps4N5BKB6cgj39ZuS8AHDwf9Qkwekv6s8oVIP7cC_e_-Jw3yX5rR_-e8RpWgEHpWVsD_UebYpuw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">oncxerna.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Navicixizumab<\/strong>\n      <\/p>\n<p align=\"justify\">Navicixizumab is an anti-DLL4\/VEGF bispecific antibody that demonstrated antitumor activity in patients who have progressed on Avastin<sup>\u00ae<\/sup> (bevacizumab) in a Phase 1a\/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal, or fallopian tube cancer in patients who have received at least three prior therapies and\/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.<\/p>\n<p align=\"justify\">\n        <strong>About Bavituximab<\/strong>\n      <\/p>\n<p align=\"justify\">Bavituximab is an antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. OncXerna\u2019s clinical trials currently combine bavituximab with KEYTRUDA<sup>\u00ae<\/sup> to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.<\/p>\n<p align=\"justify\">KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Ashley R. Robinson<br \/>LifeSci Partners, LLC<br \/>arr@lifesciadvisors.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/caf96822-a9bd-4684-9536-6d2430891999\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Xerna\u2122 TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports the application of Xerna\u2122 TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna\u2019s clinical-stage programs WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna\u2122 TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna\u2122 platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474506","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xerna\u2122 TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports the application of Xerna\u2122 TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna\u2019s clinical-stage programs WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna\u2122 TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna\u2122 platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over &hellip; Continue reading &quot;OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-10T12:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting\",\"datePublished\":\"2021-04-10T12:33:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/\",\"name\":\"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\",\"datePublished\":\"2021-04-10T12:33:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk","og_description":"Xerna\u2122 TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports the application of Xerna\u2122 TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna\u2019s clinical-stage programs WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna\u2122 TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna\u2122 platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over &hellip; Continue reading \"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-10T12:33:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting","datePublished":"2021-04-10T12:33:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/"},"wordCount":975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/","name":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==","datePublished":"2021-04-10T12:33:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDM4NSM0MTEzNjkyIzUwMDA3MjgxMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-provides-new-results-from-its-xerna-rna-based-biomarker-platform-at-the-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OncXerna Therapeutics Provides New Results from its Xerna\u2122 RNA-based Biomarker Platform at the AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474506"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474506\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}